カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界の卵巣がん治療薬市場2022年：市場規模予測（～2028年）

■ 英語タイトル：Global Ovarian Cancer Drugs Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR22NO19501）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR22NO19501
■ 発行日：2022年11月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：90
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界の卵巣がん治療薬市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

卵巣がん治療薬市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界の卵巣がん治療薬の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

卵巣がん治療薬市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・手術用、化学療法、放射線、生物療法

用途別セグメントは次のように区分されます。
・病院、診療所、その他

世界の卵巣がん治療薬市場の主要な市場プレーヤーは以下のとおりです。
・Bristol Myers Squibb、Eli Lilly、GlaxoSmithKline、Janssen Pharmaceuticals、Novogen、Genentech、Aetera Zenteris、Boehringer Ingelheim、Roche

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、卵巣がん治療薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な卵巣がん治療薬メーカーの企業概要、2019年～2022年までの卵巣がん治療薬の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な卵巣がん治療薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別卵巣がん治療薬の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までの卵巣がん治療薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での卵巣がん治療薬市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、および卵巣がん治療薬の産業チェーンを掲載しています。
・第13、14、15章では、卵巣がん治療薬の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- 卵巣がん治療薬の概要
- 種類別分析（2017年vs2021年vs2028年）：手術用、化学療法、放射線、生物療法
- 用途別分析（2017年vs2021年vs2028年）：病院、診療所、その他
- 世界の卵巣がん治療薬市場規模・予測
- 世界の卵巣がん治療薬生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- Bristol Myers Squibb、Eli Lilly、GlaxoSmithKline、Janssen Pharmaceuticals、Novogen、Genentech、Aetera Zenteris、Boehringer Ingelheim、Roche
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：手術用、化学療法、放射線、生物療法
・用途別分析2017年-2028年：病院、診療所、その他
・卵巣がん治療薬の北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・卵巣がん治療薬のヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・卵巣がん治療薬のアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・卵巣がん治療薬の南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・卵巣がん治療薬の中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Ovarian Cancer Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Ovarian Cancer Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital accounting for % of the Ovarian Cancer Drugs global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Surgery segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Ovarian Cancer Drugs include Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceuticals, and Novogen, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Ovarian Cancer Drugs market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Surgery
Chemotherapy
Radiation
Biological Therapy
Market segment by Application can be divided into
Hospital
Clinics
Others
The key market players for global Ovarian Cancer Drugs market are listed below:
Bristol Myers Squibb
Eli Lilly
GlaxoSmithKline
Janssen Pharmaceuticals
Novogen
Genentech
Aetera Zenteris
Boehringer Ingelheim
Roche
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Ovarian Cancer Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Ovarian Cancer Drugs, with price, sales, revenue and global market share of Ovarian Cancer Drugs from 2019 to 2022.
Chapter 3, the Ovarian Cancer Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Ovarian Cancer Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Ovarian Cancer Drugs market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Ovarian Cancer Drugs.
Chapter 13, 14, and 15, to describe Ovarian Cancer Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Ovarian Cancer Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Ovarian Cancer Drugs Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Surgery
1.2.3 Chemotherapy
1.2.4 Radiation
1.2.5 Biological Therapy
1.3 Market Analysis by Application
1.3.1 Overview: Global Ovarian Cancer Drugs Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Others
1.4 Global Ovarian Cancer Drugs Market Size & Forecast
1.4.1 Global Ovarian Cancer Drugs Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Ovarian Cancer Drugs Sales in Volume (2017-2028)
1.4.3 Global Ovarian Cancer Drugs Price (2017-2028)
1.5 Global Ovarian Cancer Drugs Production Capacity Analysis
1.5.1 Global Ovarian Cancer Drugs Total Production Capacity (2017-2028)
1.5.2 Global Ovarian Cancer Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Ovarian Cancer Drugs Market Drivers
1.6.2 Ovarian Cancer Drugs Market Restraints
1.6.3 Ovarian Cancer Drugs Trends Analysis
2 Manufacturers Profiles
2.1 Bristol Myers Squibb
2.1.1 Bristol Myers Squibb Details
2.1.2 Bristol Myers Squibb Major Business
2.1.3 Bristol Myers Squibb Ovarian Cancer Drugs Product and Services
2.1.4 Bristol Myers Squibb Ovarian Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Eli Lilly
2.2.1 Eli Lilly Details
2.2.2 Eli Lilly Major Business
2.2.3 Eli Lilly Ovarian Cancer Drugs Product and Services
2.2.4 Eli Lilly Ovarian Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 GlaxoSmithKline
2.3.1 GlaxoSmithKline Details
2.3.2 GlaxoSmithKline Major Business
2.3.3 GlaxoSmithKline Ovarian Cancer Drugs Product and Services
2.3.4 GlaxoSmithKline Ovarian Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Janssen Pharmaceuticals
2.4.1 Janssen Pharmaceuticals Details
2.4.2 Janssen Pharmaceuticals Major Business
2.4.3 Janssen Pharmaceuticals Ovarian Cancer Drugs Product and Services
2.4.4 Janssen Pharmaceuticals Ovarian Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Novogen
2.5.1 Novogen Details
2.5.2 Novogen Major Business
2.5.3 Novogen Ovarian Cancer Drugs Product and Services
2.5.4 Novogen Ovarian Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Genentech
2.6.1 Genentech Details
2.6.2 Genentech Major Business
2.6.3 Genentech Ovarian Cancer Drugs Product and Services
2.6.4 Genentech Ovarian Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Aetera Zenteris
2.7.1 Aetera Zenteris Details
2.7.2 Aetera Zenteris Major Business
2.7.3 Aetera Zenteris Ovarian Cancer Drugs Product and Services
2.7.4 Aetera Zenteris Ovarian Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Boehringer Ingelheim
2.8.1 Boehringer Ingelheim Details
2.8.2 Boehringer Ingelheim Major Business
2.8.3 Boehringer Ingelheim Ovarian Cancer Drugs Product and Services
2.8.4 Boehringer Ingelheim Ovarian Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Roche
2.9.1 Roche Details
2.9.2 Roche Major Business
2.9.3 Roche Ovarian Cancer Drugs Product and Services
2.9.4 Roche Ovarian Cancer Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Ovarian Cancer Drugs Breakdown Data by Manufacturer
3.1 Global Ovarian Cancer Drugs Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Ovarian Cancer Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Ovarian Cancer Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Ovarian Cancer Drugs Manufacturer Market Share in 2021
3.4.2 Top 6 Ovarian Cancer Drugs Manufacturer Market Share in 2021
3.5 Global Ovarian Cancer Drugs Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Ovarian Cancer Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Ovarian Cancer Drugs Market Size by Region
4.1.1 Global Ovarian Cancer Drugs Sales in Volume by Region (2017-2028)
4.1.2 Global Ovarian Cancer Drugs Revenue by Region (2017-2028)
4.2 North America Ovarian Cancer Drugs Revenue (2017-2028)
4.3 Europe Ovarian Cancer Drugs Revenue (2017-2028)
4.4 Asia-Pacific Ovarian Cancer Drugs Revenue (2017-2028)
4.5 South America Ovarian Cancer Drugs Revenue (2017-2028)
4.6 Middle East and Africa Ovarian Cancer Drugs Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Ovarian Cancer Drugs Sales in Volume by Type (2017-2028)
5.2 Global Ovarian Cancer Drugs Revenue by Type (2017-2028)
5.3 Global Ovarian Cancer Drugs Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Ovarian Cancer Drugs Sales in Volume by Application (2017-2028)
6.2 Global Ovarian Cancer Drugs Revenue by Application (2017-2028)
6.3 Global Ovarian Cancer Drugs Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Ovarian Cancer Drugs Sales by Type (2017-2028)
7.2 North America Ovarian Cancer Drugs Sales by Application (2017-2028)
7.3 North America Ovarian Cancer Drugs Market Size by Country
7.3.1 North America Ovarian Cancer Drugs Sales in Volume by Country (2017-2028)
7.3.2 North America Ovarian Cancer Drugs Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Ovarian Cancer Drugs Sales by Type (2017-2028)
8.2 Europe Ovarian Cancer Drugs Sales by Application (2017-2028)
8.3 Europe Ovarian Cancer Drugs Market Size by Country
8.3.1 Europe Ovarian Cancer Drugs Sales in Volume by Country (2017-2028)
8.3.2 Europe Ovarian Cancer Drugs Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Ovarian Cancer Drugs Sales by Type (2017-2028)
9.2 Asia-Pacific Ovarian Cancer Drugs Sales by Application (2017-2028)
9.3 Asia-Pacific Ovarian Cancer Drugs Market Size by Region
9.3.1 Asia-Pacific Ovarian Cancer Drugs Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Ovarian Cancer Drugs Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Ovarian Cancer Drugs Sales by Type (2017-2028)
10.2 South America Ovarian Cancer Drugs Sales by Application (2017-2028)
10.3 South America Ovarian Cancer Drugs Market Size by Country
10.3.1 South America Ovarian Cancer Drugs Sales in Volume by Country (2017-2028)
10.3.2 South America Ovarian Cancer Drugs Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Ovarian Cancer Drugs Sales by Type (2017-2028)
11.2 Middle East & Africa Ovarian Cancer Drugs Sales by Application (2017-2028)
11.3 Middle East & Africa Ovarian Cancer Drugs Market Size by Country
11.3.1 Middle East & Africa Ovarian Cancer Drugs Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Ovarian Cancer Drugs Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Ovarian Cancer Drugs and Key Manufacturers
12.2 Manufacturing Costs Percentage of Ovarian Cancer Drugs
12.3 Ovarian Cancer Drugs Production Process
12.4 Ovarian Cancer Drugs Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Ovarian Cancer Drugs Typical Distributors
13.3 Ovarian Cancer Drugs Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Ovarian Cancer Drugs Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Ovarian Cancer Drugs Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Bristol Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 4. Bristol Myers Squibb Major Business
Table 5. Bristol Myers Squibb Ovarian Cancer Drugs Product and Services
Table 6. Bristol Myers Squibb Ovarian Cancer Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 8. Eli Lilly Major Business
Table 9. Eli Lilly Ovarian Cancer Drugs Product and Services
Table 10. Eli Lilly Ovarian Cancer Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 12. GlaxoSmithKline Major Business
Table 13. GlaxoSmithKline Ovarian Cancer Drugs Product and Services
Table 14. GlaxoSmithKline Ovarian Cancer Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Janssen Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 16. Janssen Pharmaceuticals Major Business
Table 17. Janssen Pharmaceuticals Ovarian Cancer Drugs Product and Services
Table 18. Janssen Pharmaceuticals Ovarian Cancer Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Novogen Basic Information, Manufacturing Base and Competitors
Table 20. Novogen Major Business
Table 21. Novogen Ovarian Cancer Drugs Product and Services
Table 22. Novogen Ovarian Cancer Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Genentech Basic Information, Manufacturing Base and Competitors
Table 24. Genentech Major Business
Table 25. Genentech Ovarian Cancer Drugs Product and Services
Table 26. Genentech Ovarian Cancer Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Aetera Zenteris Basic Information, Manufacturing Base and Competitors
Table 28. Aetera Zenteris Major Business
Table 29. Aetera Zenteris Ovarian Cancer Drugs Product and Services
Table 30. Aetera Zenteris Ovarian Cancer Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 32. Boehringer Ingelheim Major Business
Table 33. Boehringer Ingelheim Ovarian Cancer Drugs Product and Services
Table 34. Boehringer Ingelheim Ovarian Cancer Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Roche Basic Information, Manufacturing Base and Competitors
Table 36. Roche Major Business
Table 37. Roche Ovarian Cancer Drugs Product and Services
Table 38. Roche Ovarian Cancer Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Global Ovarian Cancer Drugs Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 40. Global Ovarian Cancer Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 41. Market Position of Manufacturers in Ovarian Cancer Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 42. Global Ovarian Cancer Drugs Production Capacity by Company, (K Units): 2020 VS 2021
Table 43. Head Office and Ovarian Cancer Drugs Production Site of Key Manufacturer
Table 44. Ovarian Cancer Drugs New Entrant and Capacity Expansion Plans
Table 45. Ovarian Cancer Drugs Mergers & Acquisitions in the Past Five Years
Table 46. Global Ovarian Cancer Drugs Sales by Region (2017-2022) & (K Units)
Table 47. Global Ovarian Cancer Drugs Sales by Region (2023-2028) & (K Units)
Table 48. Global Ovarian Cancer Drugs Revenue by Region (2017-2022) & (USD Million)
Table 49. Global Ovarian Cancer Drugs Revenue by Region (2023-2028) & (USD Million)
Table 50. Global Ovarian Cancer Drugs Sales by Type (2017-2022) & (K Units)
Table 51. Global Ovarian Cancer Drugs Sales by Type (2023-2028) & (K Units)
Table 52. Global Ovarian Cancer Drugs Revenue by Type (2017-2022) & (USD Million)
Table 53. Global Ovarian Cancer Drugs Revenue by Type (2023-2028) & (USD Million)
Table 54. Global Ovarian Cancer Drugs Price by Type (2017-2022) & (USD/Unit)
Table 55. Global Ovarian Cancer Drugs Price by Type (2023-2028) & (USD/Unit)
Table 56. Global Ovarian Cancer Drugs Sales by Application (2017-2022) & (K Units)
Table 57. Global Ovarian Cancer Drugs Sales by Application (2023-2028) & (K Units)
Table 58. Global Ovarian Cancer Drugs Revenue by Application (2017-2022) & (USD Million)
Table 59. Global Ovarian Cancer Drugs Revenue by Application (2023-2028) & (USD Million)
Table 60. Global Ovarian Cancer Drugs Price by Application (2017-2022) & (USD/Unit)
Table 61. Global Ovarian Cancer Drugs Price by Application (2023-2028) & (USD/Unit)
Table 62. North America Ovarian Cancer Drugs Sales by Country (2017-2022) & (K Units)
Table 63. North America Ovarian Cancer Drugs Sales by Country (2023-2028) & (K Units)
Table 64. North America Ovarian Cancer Drugs Revenue by Country (2017-2022) & (USD Million)
Table 65. North America Ovarian Cancer Drugs Revenue by Country (2023-2028) & (USD Million)
Table 66. North America Ovarian Cancer Drugs Sales by Type (2017-2022) & (K Units)
Table 67. North America Ovarian Cancer Drugs Sales by Type (2023-2028) & (K Units)
Table 68. North America Ovarian Cancer Drugs Sales by Application (2017-2022) & (K Units)
Table 69. North America Ovarian Cancer Drugs Sales by Application (2023-2028) & (K Units)
Table 70. Europe Ovarian Cancer Drugs Sales by Country (2017-2022) & (K Units)
Table 71. Europe Ovarian Cancer Drugs Sales by Country (2023-2028) & (K Units)
Table 72. Europe Ovarian Cancer Drugs Revenue by Country (2017-2022) & (USD Million)
Table 73. Europe Ovarian Cancer Drugs Revenue by Country (2023-2028) & (USD Million)
Table 74. Europe Ovarian Cancer Drugs Sales by Type (2017-2022) & (K Units)
Table 75. Europe Ovarian Cancer Drugs Sales by Type (2023-2028) & (K Units)
Table 76. Europe Ovarian Cancer Drugs Sales by Application (2017-2022) & (K Units)
Table 77. Europe Ovarian Cancer Drugs Sales by Application (2023-2028) & (K Units)
Table 78. Asia-Pacific Ovarian Cancer Drugs Sales by Region (2017-2022) & (K Units)
Table 79. Asia-Pacific Ovarian Cancer Drugs Sales by Region (2023-2028) & (K Units)
Table 80. Asia-Pacific Ovarian Cancer Drugs Revenue by Region (2017-2022) & (USD Million)
Table 81. Asia-Pacific Ovarian Cancer Drugs Revenue by Region (2023-2028) & (USD Million)
Table 82. Asia-Pacific Ovarian Cancer Drugs Sales by Type (2017-2022) & (K Units)
Table 83. Asia-Pacific Ovarian Cancer Drugs Sales by Type (2023-2028) & (K Units)
Table 84. Asia-Pacific Ovarian Cancer Drugs Sales by Application (2017-2022) & (K Units)
Table 85. Asia-Pacific Ovarian Cancer Drugs Sales by Application (2023-2028) & (K Units)
Table 86. South America Ovarian Cancer Drugs Sales by Country (2017-2022) & (K Units)
Table 87. South America Ovarian Cancer Drugs Sales by Country (2023-2028) & (K Units)
Table 88. South America Ovarian Cancer Drugs Revenue by Country (2017-2022) & (USD Million)
Table 89. South America Ovarian Cancer Drugs Revenue by Country (2023-2028) & (USD Million)
Table 90. South America Ovarian Cancer Drugs Sales by Type (2017-2022) & (K Units)
Table 91. South America Ovarian Cancer Drugs Sales by Type (2023-2028) & (K Units)
Table 92. South America Ovarian Cancer Drugs Sales by Application (2017-2022) & (K Units)
Table 93. South America Ovarian Cancer Drugs Sales by Application (2023-2028) & (K Units)
Table 94. Middle East & Africa Ovarian Cancer Drugs Sales by Region (2017-2022) & (K Units)
Table 95. Middle East & Africa Ovarian Cancer Drugs Sales by Region (2023-2028) & (K Units)
Table 96. Middle East & Africa Ovarian Cancer Drugs Revenue by Region (2017-2022) & (USD Million)
Table 97. Middle East & Africa Ovarian Cancer Drugs Revenue by Region (2023-2028) & (USD Million)
Table 98. Middle East & Africa Ovarian Cancer Drugs Sales by Type (2017-2022) & (K Units)
Table 99. Middle East & Africa Ovarian Cancer Drugs Sales by Type (2023-2028) & (K Units)
Table 100. Middle East & Africa Ovarian Cancer Drugs Sales by Application (2017-2022) & (K Units)
Table 101. Middle East & Africa Ovarian Cancer Drugs Sales by Application (2023-2028) & (K Units)
Table 102. Ovarian Cancer Drugs Raw Material
Table 103. Key Manufacturers of Ovarian Cancer Drugs Raw Materials
Table 104. Direct Channel Pros & Cons
Table 105. Indirect Channel Pros & Cons
Table 106. Ovarian Cancer Drugs Typical Distributors
Table 107. Ovarian Cancer Drugs Typical Customers
List of Figures
Figure 1. Ovarian Cancer Drugs Picture
Figure 2. Global Ovarian Cancer Drugs Revenue Market Share by Type in 2021
Figure 3. Surgery
Figure 4. Chemotherapy
Figure 5. Radiation
Figure 6. Biological Therapy
Figure 7. Global Ovarian Cancer Drugs Revenue Market Share by Application in 2021
Figure 8. Hospital
Figure 9. Clinics
Figure 10. Others
Figure 11. Global Ovarian Cancer Drugs Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 12. Global Ovarian Cancer Drugs Revenue and Forecast (2017-2028) & (USD Million)
Figure 13. Global Ovarian Cancer Drugs Sales (2017-2028) & (K Units)
Figure 14. Global Ovarian Cancer Drugs Price (2017-2028) & (USD/Unit)
Figure 15. Global Ovarian Cancer Drugs Production Capacity (2017-2028) & (K Units)
Figure 16. Global Ovarian Cancer Drugs Production Capacity by Geographic Region: 2022 VS 2028
Figure 17. Ovarian Cancer Drugs Market Drivers
Figure 18. Ovarian Cancer Drugs Market Restraints
Figure 19. Ovarian Cancer Drugs Market Trends
Figure 20. Global Ovarian Cancer Drugs Sales Market Share by Manufacturer in 2021
Figure 21. Global Ovarian Cancer Drugs Revenue Market Share by Manufacturer in 2021
Figure 22. Ovarian Cancer Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 23. Top 3 Ovarian Cancer Drugs Manufacturer (Revenue) Market Share in 2021
Figure 24. Top 6 Ovarian Cancer Drugs Manufacturer (Revenue) Market Share in 2021
Figure 25. Global Ovarian Cancer Drugs Sales Market Share by Region (2017-2028)
Figure 26. Global Ovarian Cancer Drugs Revenue Market Share by Region (2017-2028)
Figure 27. North America Ovarian Cancer Drugs Revenue (2017-2028) & (USD Million)
Figure 28. Europe Ovarian Cancer Drugs Revenue (2017-2028) & (USD Million)
Figure 29. Asia-Pacific Ovarian Cancer Drugs Revenue (2017-2028) & (USD Million)
Figure 30. South America Ovarian Cancer Drugs Revenue (2017-2028) & (USD Million)
Figure 31. Middle East & Africa Ovarian Cancer Drugs Revenue (2017-2028) & (USD Million)
Figure 32. Global Ovarian Cancer Drugs Sales Market Share by Type (2017-2028)
Figure 33. Global Ovarian Cancer Drugs Revenue Market Share by Type (2017-2028)
Figure 34. Global Ovarian Cancer Drugs Price by Type (2017-2028) & (USD/Unit)
Figure 35. Global Ovarian Cancer Drugs Sales Market Share by Application (2017-2028)
Figure 36. Global Ovarian Cancer Drugs Revenue Market Share by Application (2017-2028)
Figure 37. Global Ovarian Cancer Drugs Price by Application (2017-2028) & (USD/Unit)
Figure 38. North America Ovarian Cancer Drugs Sales Market Share by Type (2017-2028)
Figure 39. North America Ovarian Cancer Drugs Sales Market Share by Application (2017-2028)
Figure 40. North America Ovarian Cancer Drugs Sales Market Share by Country (2017-2028)
Figure 41. North America Ovarian Cancer Drugs Revenue Market Share by Country (2017-2028)
Figure 42. United States Ovarian Cancer Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Canada Ovarian Cancer Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Mexico Ovarian Cancer Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Europe Ovarian Cancer Drugs Sales Market Share by Type (2017-2028)
Figure 46. Europe Ovarian Cancer Drugs Sales Market Share by Application (2017-2028)
Figure 47. Europe Ovarian Cancer Drugs Sales Market Share by Country (2017-2028)
Figure 48. Europe Ovarian Cancer Drugs Revenue Market Share by Country (2017-2028)
Figure 49. Germany Ovarian Cancer Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. France Ovarian Cancer Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. United Kingdom Ovarian Cancer Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Russia Ovarian Cancer Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Italy Ovarian Cancer Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Asia-Pacific Ovarian Cancer Drugs Sales Market Share by Region (2017-2028)
Figure 55. Asia-Pacific Ovarian Cancer Drugs Sales Market Share by Application (2017-2028)
Figure 56. Asia-Pacific Ovarian Cancer Drugs Sales Market Share by Region (2017-2028)
Figure 57. Asia-Pacific Ovarian Cancer Drugs Revenue Market Share by Region (2017-2028)
Figure 58. China Ovarian Cancer Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Japan Ovarian Cancer Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Korea Ovarian Cancer Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. India Ovarian Cancer Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Southeast Asia Ovarian Cancer Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Australia Ovarian Cancer Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. South America Ovarian Cancer Drugs Sales Market Share by Type (2017-2028)
Figure 65. South America Ovarian Cancer Drugs Sales Market Share by Application (2017-2028)
Figure 66. South America Ovarian Cancer Drugs Sales Market Share by Country (2017-2028)
Figure 67. South America Ovarian Cancer Drugs Revenue Market Share by Country (2017-2028)
Figure 68. Brazil Ovarian Cancer Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Argentina Ovarian Cancer Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Middle East & Africa Ovarian Cancer Drugs Sales Market Share by Type (2017-2028)
Figure 71. Middle East & Africa Ovarian Cancer Drugs Sales Market Share by Application (2017-2028)
Figure 72. Middle East & Africa Ovarian Cancer Drugs Sales Market Share by Region (2017-2028)
Figure 73. Middle East & Africa Ovarian Cancer Drugs Revenue Market Share by Region (2017-2028)
Figure 74. Turkey Ovarian Cancer Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Egypt Ovarian Cancer Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Saudi Arabia Ovarian Cancer Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. South Africa Ovarian Cancer Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Manufacturing Cost Structure Analysis of Ovarian Cancer Drugs in 2021
Figure 79. Manufacturing Process Analysis of Ovarian Cancer Drugs
Figure 80. Ovarian Cancer Drugs Industrial Chain
Figure 81. Sales Channel: Direct Channel vs Indirect Channel
Figure 82. Methodology
Figure 83. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 世界の乳がん治療薬市場2022年：市場規模予測（～2028年）
  • 世界のがん用PARP阻害剤市場2022年：市場規模予測（～2028年）
  • 世界のメトトレキサート（MTX）医薬品市場2022年：市場規模予測（～2028年）
  • 世界の転移性がん治療薬市場2022年：市場規模予測（～2028年）
  • 世界のメトトレキサート（MTX）経口液市場2022年：市場規模予測（～2028年）
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR22NO19501 )"世界の卵巣がん治療薬市場2022年：市場規模予測（～2028年）" (英文：Global Ovarian Cancer Drugs Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。